Thank you, Jack. Good morning, and thanks for joining our call today. Since our last earnings call and tariff implementations, market volatility and recession expectations have increased significantly, creating uncertainty for both businesses and households, the early recovery of real estate has likely been put on hold until we have more clarity on the scale and impact of the tariff regime. That said, we do believe real estate is better positioned for this environment compared to past cycles and other asset classes, given the reset and values over the last three years in times like this, the first thing we think about is defense. It's a get your house in order mentality. And to that end, we are in a very good position. We have no corporate maturities until 2030 having just upsized and extended our corporate revolver for new five year term and refinanced our Term Loan B, with a new seven year facility, we have ample liquidity with over 700 million today. Given this secure position, we will remain on offense, actively looking to reinvest repayments into new originations. In terms of what we are seeing in the real estate credit market, it is still functioning, and all market participants remain active, including the banking sector, warehouse financing and senior loan spreads are approximately 10 to 15 basis points wider, while the transitional loan sector spreads are approximately 15 to 20 basis points wider. BMBF spreads have been more volatile and are currently 50 to 75 basis points wider. Many owners are now coming to us for a balance sheet solution to avoid the capital markets volatility. From an opportunity perspective, it's significant. Our pipeline is the largest it's ever been, totaling over 30 billion, and it's very high quality. I expect this market will lead our sponsors to seek out more short term bridge loans instead of testing the investment sales market, interestingly, our repayment expectations have increased since our last call. As we articulated last quarter, repayments are expected to exceed $1 billion this year, and we are tracking well above that. We had an active quarter and closed four loans for a total of 376,000,080% 80% of which were secured by Class A, multi-family properties. It had a weighted average LTV of 69% and a coupon of SOFR plus 277 basis points repayments in the. Quarter, we're 180, 4 million, and along with future funding from existing loans, our net fundings totaled 220, 2 million. We are actively looking at opportunities to diversify our portfolio and add duration. To that end, we are focused on the European lending market. We have built a strong team over the last few years, we are also looking at new issue, CMBS, conduit V pieces, where we can leverage our position as one of the largest market participants, as well as k star, which is our rated special servicer. Turning next to risk ratings, we downgraded two loans this quarter. First, a Raleigh, North Carolina multifamily loan, from a four rated loan to a five rated loan. We are still evaluating numerous scenarios for this loan, and are engaged in workout discussions which could lead to an ownership position. Second, Boston life science, from a three rated to a four rated loan due to current occupancy trends with the two downgrades in the quarter and therefore increased CECL provisions book value per share is $14.44 down approximately 2% compared to the prior quarter. We will continue to be transparent and proactive in managing the KREF portfolio, and will provide updates on those two loans in the coming quarters, before turning it over to Patrick. I will touch on our life science exposure. This is a sector that we believe has long term positive fundamentals, but faces cyclical headwinds, which could be exacerbated by an economic downturn or NIH funding costs, funding cuts. As a reminder, 12% of our loan portfolio is Life Science, and we have one REO property. We thought it'd be helpful to provide additional details in our supplemental which is on page 10 of the presentation. At a high level, 100% of our loan exposure is located in the top two Life Science markets, Boston and South San Francisco, and we provided construction financing for over half of our exposure. So these are very high quality and purpose built for Life Science. We've seen some green shoots as well. In March, we executed a 32,000 square foot lease in our Seattle Life Science REO property to the Institute for protein Design at the University of Washington. The tenant has created AI technologies and computationally designed protein medicines, and is led by a recent Nobel Prize winner for chemistry. With that, I'll turn it over to Patrick.